相关实验视频

Updated: Jun 27, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K

在中期-2或高风险骨髓纤维化症患者中,费德拉提尼布的暴露-反应关系

Yizhe Chen1, Yan Li1, Yongjun Xue1

  • 1Translational Medicine and Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA.

British journal of clinical pharmacology
|June 9, 2025
PubMed
概括

费德拉提尼布暴露与骨髓纤维化患者的体积和症状减少有积极的相关性. 药物是安全有效的,无论之前的鲁克索利提尼布治疗,支持400毫克的每日剂量.

关键词:
剂量 剂量 剂量 剂量 剂量暴露 响应 反应费德拉提尼布 (Fedratinib) 是一种骨髓纤维化 骨髓纤维化预防 预防 预防 预防

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

639
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

852

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...